In this post, Baker Tilly is going to analyse the most important investors in the Health Diagnostics sector.  

The Health Diagnostics market is a mature market, with a large number of companies in the market. acquisitions since 2014, a total of 469 acquisitions. The sector includes all those companies dedicated to the analysis and development of techniques and instruments that facilitate the early diagnosis of pathologies and/or diseases, until a solution is found to the problem detected. 

F-Prime Capital in the Health Diagnostics sector

F-Prime Capital is an investment management and venture capital firm that provides seed, venture and growth stage financing to start-ups in the healthcare sector, focusing on therapeutics, medical technology and health IT and services. Through specific programmes such as: enterprise software, fintech and cutting-edge technology, in Europe, Asia and the US. 

In 2018, I led a large investment round with Xilio Therapeutics, a biopharmaceutical company focused on developing highly potent and targeted immuno-oncology therapies. The financing was $168M. 

Temasek in the Health Diagnostics sector

Temasek is a company of investment based in Singapore. He focuses on the financials, transportation and energy resources (life and agribusiness) sectors seeking sustainable growth of companies and strengthening their capabilities. It aims to help provide more top-down guidance on your strategic direction and portfolio objectives: portfolio construction and analysis, quantitative strategy and performance analysis, risk management and strategy. 

Temasek is leading a $25 million investment round in Integra Holdings, where the funds contribute to the expansion and development of Integra's portfolio, providing the Hebrew University's Life Sciences innovations to the market.